The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
i do think in mci that there's opportunity for these drugs to work and and you know the fda is considering the agicanamab data right now um the there was just um last or actually at the beginning of this week data for don and mab which is a lilly study that came out at the adpd meeting showing that it met end points on almost all of the mark you know the the primary and secondary outcome measures that they had set forth so um yeah i wouldn't rule out the mci group at this point
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
i do think in mci that there's opportunity for these drugs to work